COLZYX AB

Their core work

COLZYX AB is a Swedish biotech SME developing bioactive wound dressings based on human collagen VI — a protein with documented wound healing and antimicrobial properties. Their core product exploits collagen VI's natural biological activity to create a dressing that does more than protect a wound: it actively promotes healing while fighting infection. They progressed through the EU SME Instrument in sequence, using a Phase 1 feasibility grant to validate their biomembrane concept, then securing a Phase 2 development grant of €2.5M to bring the product toward market. Their work sits at the intersection of biomaterials science, wound care, and medical device commercialization.

What they specialise in

How they've shifted over time

COLZYX's H2020 trajectory follows a single, disciplined technology development path rather than a broadening of research interests. Their first project (2018-2019) framed the work in academic-biomaterial terms — "interactive biomembranes" — suggesting they were still proving the biological mechanism. By their second project (2020-2025), the language shifted decisively toward commercialization: "the first bioactive wound dressing", with keywords anchored in product categories (wound dressing) and specific molecular inputs (human collagen VI, biomembranes). The evolution is not a change of direction but a maturation from concept validation to product development, which is exactly what the SME Instrument Phase 1→2 pathway is designed to support.

COLZYX is on a straight-line path toward market entry with a collagen VI wound dressing product — any future collaboration would most likely involve clinical validation, regulatory affairs, manufacturing scale-up, or distribution partnerships rather than further basic research.

How they like to work

COLZYX has operated exclusively as project coordinator across both H2020 grants, and the data shows zero registered consortium partners — consistent with the SME Instrument model, where a single company receives direct funding to develop its own innovation. This means they have not built a visible H2020 partner network, and their EU project experience is entirely self-directed rather than consortium-driven. A prospective partner should expect to engage with a focused, IP-owning SME that knows its technology deeply but may have limited experience managing multi-partner research consortia.

COLZYX has no registered H2020 consortium partners and no cross-country collaboration recorded in this dataset, which is typical for SME Instrument beneficiaries who receive direct company grants. Their external network, if any, is likely through clinical partners, hospitals, or distributors outside the formal H2020 structure.

What sets them apart

COLZYX appears to hold proprietary access to human collagen VI as a functional wound-care ingredient — a specific protein not commonly used in commercial wound dressings — which gives them a defensible product differentiation story. Based in Lund, Sweden, they are embedded in one of Europe's strongest life science clusters (Medicon Valley), which provides access to clinical expertise, regulatory know-how, and biotech investors. For a consortium builder in wound care, digital health, or antimicrobial resistance, COLZYX brings a ready technology asset rather than early-stage research.

Highlights from their portfolio

• WOUNDCOM
  The Phase 2 grant (€2,514,575, 2020-2025) is one of the larger SME Instrument awards and signals that the European Commission validated both the technical feasibility and commercial potential of their collagen VI wound dressing.
• WOUNDCOM
  The Phase 1 grant (2018-2019) demonstrates a clean SME Instrument progression — COLZYX is one of relatively few SMEs that successfully converted a Phase 1 feasibility study into a full Phase 2 development award.